Sean Richardson – GM, Alexion Pharma UK
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
Address: 1 Royal College St ,London, Greater London NW1 0SB, UK
Tel: +44(0) 20 7691 4906
Web: http://www.xeneticbio.com/
Xenetic is a leading UK based biopharmaceutical company providing leading edge expertise in the development of a whole new generation of drugs and vaccines.
Working with some of the largest pharmaceutical organisations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas.
We are also actively developing our own pipeline of next generation biotherapeutics based on our proprietary PolyXen andImuXen platform technologies.
Xenetic’s biopharmaceutical pipeline contains a range of product candidates which are currently under development either in-house or with biotechnology and pharmaceutical partners. The products in Xenetic’s pipeline have a multi-billion dollar market potential.
Pipeline products are based on Xenetic’s proprietary drug and vaccine delivery technologies and have been developed to offer improved performance and delivery characteristics. Xenetic’s unique delivery technologies are also able to create new high-value, differentiated proprietary products from off-patent actives.
Xenetic has established a range of partnerships with major US, European, Russian and Asian biotechnology and pharmaceutical companies to develop new protein therapeutics and vaccines. Click here to learn more about the work we do with our partners.
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
See our Cookie Privacy Policy Here
